Back to results

Prevention and Reversion of NAFLD in Obese Patients With Metabolic Syndrome by Mediterranean Diet and Physical Activity (FLIPAN)

Primary Purpose

Non Alcoholic Fatty Liver Disease

Status

Unknown status

Phase

Not Applicable

Locations

Spain

Study Type

Interventional

Intervention

Physical activity and Mediterranean Diet (PA-MD)

High meal frequency of Mediterranean Diet (HMF-MD)

Control diet (CD)

About this trial

This is an interventional prevention trial for Non Alcoholic Fatty Liver Disease focused on measuring Non Alcoholic Fatty Liver Disease, Metabolic syndrome, Mediterranean Diet, Physical activity

Eligibility Criteria

40 Years - 60 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Age between 40 and 60 years
Diagnosis of NAFLD by ultrasound
BMI ≥ 27 and < 40 kg/m2
Meeting at least 3 of 5 criteria for the metabolic syndrome [as described in the International Diabetes Federation consensus]: (1) BMI >30kg/m² or increased waist circumference: ≥ 94 cm in males; ≥ 80 cm in females; (2) Triglycerides (TG) levels ≥ 150 mg/dL (1.7 mmol/L) or specific treatment; (3) Reduced HDL cholesterol: < 40 mg/dL (1.03 mmol/L) in males; < 50 mg/dL (1.29 mmol/L) in females or specific treatment; (4) Raised blood pressure: systolic BP ≥ 130 or diastolic BP ≥ 85 mm Hg or treatment of previously diagnosed hypertension; (5) Raised fasting plasma glucose (FPG) ≥ 100 mg/dL (5.6 mmol/L), or previously diagnosed type 2 diabetes
Written informed consent

Exclusion Criteria:

Inability or unwillingness to give informed consent or communicate with staff study
Documented history of prior cardiovascular disease [angina; myocardial infarction; coronary revascularization procedures; stroke (ischemic or hemorrhagic including transient ischemic attacks); symptomatic peripheral artery disease that required surgery or was diagnosed with vascular imaging techniques; ventricular arrhythmia; uncontrolled atrial fibrillation; congestive heart failure (New York Heart Association Class III or IV); hypertrophic myocardiopathy; and history of aortic aneurism >=5.5cm in diameter or aortic aneurism surgery]
Documented history of prior liver diseases (other than NAFLD)
Active cancer or a history of malignancy in the last 5 years
Low predicted probability to change food habits according to the Stages of Change Model (Nigg, 1999)
Unwillingness or inability to adhere to the dietary and physical activity intervention over the entire period of the study
Failure to follow scheduled visits
Weight loss (>5 kg) during 6 months prior to visit
Previous surgical procedures for weight loss or scheduled bariatric surgery within the next 12 months
Use of weight loss medications during 6 months prior to visit
Previous history of bowel resection, inflammatory bowel disease
Obesity associated with endocrine disease (except treated hypothyroidism)
Allergy to Mediterranean diet foods or components
Severe psychiatric disorders (schizophrenia, bipolar disorder, eating disorders, or depression with hospitalization within the last 6 months) or Beck Depression Inventory score > 30
Severe condition with less than 24 months life expectancy
Chronic abuse of drugs or alcohol (>21 and >14 units of alcohol a week for men and women, respectively; 1 unit = 125 mL of wine)
Treatment with steroids
Pregnancy

Sites / Locations

University of the Balearic Islands

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Active Comparator

Arm Label

1st group: Physical Activity and Mediterranean Diet (PA-MD)

2nd group: High Meal Frequency of Mediterranean Diet (HMF-MD)

3rd group: Control diet (CD)

Arm Description

A first group of participants will be advised to reduce their caloric intake by 25-30% with a macronutrients distribution of 35-40% fat, 20% proteins, and 40-45% carbohydrates. Healthy fats (a maximum of 8-10% from saturated fats, >20% from monounsaturated fats, >10% from polyunsaturated fats and <300 mg/day of cholesterol) and low glycaemic index foods rich in fibre (not less than 30-35g /day) are strongly advised, together with foods rich in antioxidants, namely fruits and vegetables. Such diet reflects the traditional Mediterranean Diet described in the PREDIMED (Primary Prevention of Cardiovascular Disease with a Mediterranean Diet)-Plus study. As for physical activity, patients the participants will be recommended a 35 minutes interval training session three times a week. Physical activity sessions of 35 minutes will consist of 5 minutes warm-up, 20 minutes interval training, and 10 minutes breathing and stretching.

A second group of participants will be advised to reduce their caloric intake by 25-30% with a macronutrients distribution of 30-35% fat, 25% proteins, and 40-45% carbohydrates. Healthy fats and low glycaemic index foods will be strongly advised, together with foods rich in antioxidants, namely fruits and vegetables. Participants will be advised to consume 7 meals a day, gradually reducing the caloric content at each main meal, and to walk 10.000 steps a day.

A third group of participants will be advised to reduce their caloric intake by 25-30% with a macronutrients distribution of 30% fat, 15% proteins, and 55% carbohydrates, and maintain an adequate fibre (25g/day) and cholesterol (<250mg/day) intake. Meal frequency will be of 3-5 meals a day. Moreover, the participants will be advised to walk 10.000 steps a day.

Outcomes

Primary Outcome Measures

Changes in liver steatosis

The primary outcome is to measure the change of liver steatosis (expressed as percentage of liver steatosis) after applying a different intervention to each group (PA-MD; HMF-MD; or CD) of participants with metabolic syndrome. It will be measured (at baseline, and after 6, 12 and 24 months of intervention) by means of a 1.5-T Magnetic Resonance Imaging (MRI) (Signa Explorer 1.5T, General Electric Healthcare, Chicago, Illinois., U.S.A) by using a 12-channel phased-array coil.

Secondary Outcome Measures

Changes in liver fibrosis

The secondary otucome is to measure the changes of liver fibrosis (expressed as percentage of liver fibrosis) after applying a different intervention to each group (PA-MD; HMF-MD; or CD) of participants with metabolic syndrome. It will be measured (at baseline, and after 6, 12 and 24 months of intervention) by using Shear Wave Measurement (SWM) (Hitachi Ltd, Japan) and the echograph Arietta V70 (Hitachi Medical System Europe Holding AG, Steinhausen, Switzerland).

Full Information

NCT ID

NCT04442620

First Posted

January 28, 2020

Last Updated

June 19, 2020

Sponsor

University of the Balearic Islands

Collaborators

Fundació La Marató de TV3

1. Study Identification

Unique Protocol Identification Number

NCT04442620

Brief Title

Prevention and Reversion of NAFLD in Obese Patients With Metabolic Syndrome by Mediterranean Diet and Physical Activity

Acronym

FLIPAN

Official Title

Prevention and Reversion of Non-Alcoholic Fatty Liver Disease in Obese Patients With Metabolic Syndrome by Mediterranean Diet and Physical Activity

Study Type

Interventional

2. Study Status

Record Verification Date

June 2020

Overall Recruitment Status

Unknown status

Study Start Date

October 26, 2017 (Actual)

Primary Completion Date

November 29, 2019 (Actual)

Study Completion Date

December 1, 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Principal Investigator

Name of the Sponsor

University of the Balearic Islands

Collaborators

Fundació La Marató de TV3

4. Oversight

Studies a U.S. FDA-regulated Drug Product

Studies a U.S. FDA-regulated Device Product

Data Monitoring Committee

5. Study Description

Brief Summary

This prospective randomized trial evaluates the role of customized dietary and physical activity intervention on the progression of Non-Alcoholic Fatty Liver Disease (NAFLD) in patients with obesity and presenting at least three of the main Metabolic Syndrome traits. The project proposes a personalized nutritional intervention based on a Mediterranean customized diet which introduces plenty of antioxidant and anti-inflammatory bioactive components, coupled with physical activity promotion to prevent and reverse NAFLD among obese patients with metabolic syndrome. This will be compared with two more dietary strategies including a Mediterranean Diet intervention with seven meals a day and the conventional dietary approach proposed by the American Association for the Study of Liver Diseases (AASLD).

Detailed Description

There is currently no licensed pharmacological treatment for reversing Non-Alcoholic Fatty Liver Disease (NAFLD), this is why nutritional and lifestyle strategies are pivotal to ameliorate risk factors and prevent disease progression. Weight loss achieved by a weight loss diet and exercise is certainly the principal treatment for the amelioration of fatty liver, nevertheless quality of diet composition could also play a crucial role. Since oxidative stress and inflammation have been cited among the mechanisms involved in NAFLD, foods containing antioxidant and anti-inflammatory bioactive components should be considered when designing a nutritionally sound diet. The Mediterranean Diet, naturally rich in antioxidants and antinflammatory foods, together with personalised physical activity could have a variety of positive health effects, including the slowing down of degenerative diseases such as liver steatosis. The present study aims to compare and evaluate the efficacy of three interventions on the pathophysiological mechanisms that may affect changes in liver fat deposits and progression of NAFLD in patients with obesity and presenting at least three of the main Metabolic Syndrome traits. The first intervention group receives a caloric restricted Mediterranean Diet coupled with physical activity (delivered through guided gym classes); the second group receives a caloric restricted Mediterranean Diet distributed over 7 meals and advise to walk 10.000 steps a day; the third group receives the conventional diet proposed by the American Association for the Study of Liver Diseases (AASLD) and advise to walk 10.000 steps a day.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Non Alcoholic Fatty Liver Disease

Keywords

Non Alcoholic Fatty Liver Disease, Metabolic syndrome, Mediterranean Diet, Physical activity

7. Study Design

Primary Purpose

Prevention

Study Phase

Not Applicable

Interventional Study Model

Parallel Assignment

Masking

None (Open Label)

Allocation

Randomized

Enrollment

150 (Actual)

8. Arms, Groups, and Interventions

Arm Title

1st group: Physical Activity and Mediterranean Diet (PA-MD)

Arm Type

Experimental

Arm Description

Arm Title

2nd group: High Meal Frequency of Mediterranean Diet (HMF-MD)

Arm Type

Experimental

Arm Description

Arm Title

3rd group: Control diet (CD)

Arm Type

Active Comparator

Arm Description

Intervention Type

Other

Intervention Name(s)

Physical activity and Mediterranean Diet (PA-MD)

Intervention Description

Physical Activity plus caloric restricted Mediterranean diet

Intervention Type

Other

Intervention Name(s)

High meal frequency of Mediterranean Diet (HMF-MD)

Intervention Description

High meal frequency of unaltered Mediterranean diet

Intervention Type

Other

Intervention Name(s)

Control diet (CD)

Intervention Description

Control Diet

Primary Outcome Measure Information:

Title

Changes in liver steatosis

Description

Time Frame

At baseline, 6, 12 and 24 months

Secondary Outcome Measure Information:

Title

Changes in liver fibrosis

Description

Time Frame

At baseline, 6, 12 and 24 months

10. Eligibility

Sex

All

Minimum Age & Unit of Time

40 Years

Maximum Age & Unit of Time

60 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: Age between 40 and 60 years Diagnosis of NAFLD by ultrasound BMI ≥ 27 and < 40 kg/m2 Meeting at least 3 of 5 criteria for the metabolic syndrome [as described in the International Diabetes Federation consensus]: (1) BMI >30kg/m² or increased waist circumference: ≥ 94 cm in males; ≥ 80 cm in females; (2) Triglycerides (TG) levels ≥ 150 mg/dL (1.7 mmol/L) or specific treatment; (3) Reduced HDL cholesterol: < 40 mg/dL (1.03 mmol/L) in males; < 50 mg/dL (1.29 mmol/L) in females or specific treatment; (4) Raised blood pressure: systolic BP ≥ 130 or diastolic BP ≥ 85 mm Hg or treatment of previously diagnosed hypertension; (5) Raised fasting plasma glucose (FPG) ≥ 100 mg/dL (5.6 mmol/L), or previously diagnosed type 2 diabetes Written informed consent Exclusion Criteria: Inability or unwillingness to give informed consent or communicate with staff study Documented history of prior cardiovascular disease [angina; myocardial infarction; coronary revascularization procedures; stroke (ischemic or hemorrhagic including transient ischemic attacks); symptomatic peripheral artery disease that required surgery or was diagnosed with vascular imaging techniques; ventricular arrhythmia; uncontrolled atrial fibrillation; congestive heart failure (New York Heart Association Class III or IV); hypertrophic myocardiopathy; and history of aortic aneurism >=5.5cm in diameter or aortic aneurism surgery] Documented history of prior liver diseases (other than NAFLD) Active cancer or a history of malignancy in the last 5 years Low predicted probability to change food habits according to the Stages of Change Model (Nigg, 1999) Unwillingness or inability to adhere to the dietary and physical activity intervention over the entire period of the study Failure to follow scheduled visits Weight loss (>5 kg) during 6 months prior to visit Previous surgical procedures for weight loss or scheduled bariatric surgery within the next 12 months Use of weight loss medications during 6 months prior to visit Previous history of bowel resection, inflammatory bowel disease Obesity associated with endocrine disease (except treated hypothyroidism) Allergy to Mediterranean diet foods or components Severe psychiatric disorders (schizophrenia, bipolar disorder, eating disorders, or depression with hospitalization within the last 6 months) or Beck Depression Inventory score > 30 Severe condition with less than 24 months life expectancy Chronic abuse of drugs or alcohol (>21 and >14 units of alcohol a week for men and women, respectively; 1 unit = 125 mL of wine) Treatment with steroids Pregnancy

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Josep A Tur, PhD

Organizational Affiliation

University of the Balearic Islands

Official's Role

Principal Investigator

Facility Information:

Facility Name

University of the Balearic Islands

City

Palma

State/Province

Balearic Islands

ZIP/Postal Code

07122

Country

Spain

12. IPD Sharing Statement

Plan to Share IPD

IPD Sharing Plan Description

There are restrictions on the availability of data for the FLIPAN trial, due to the signed consent agreements around data sharing, which only allow access to external researchers for studies following the project purposes. Requestors wishing to access the FLIPAN trial data used in this study can make a request to the FLIPAN trial. Steering Committee chair: pep.tur@uib.es. The request will then be passed to members of the FLIPAN Steering Committee for deliberation.

Learn more about this trial

Prevention and Reversion of NAFLD in Obese Patients With Metabolic Syndrome by Mediterranean Diet and Physical Activity

We'll reach out to this number within 24 hrs